{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:39:00Z","timestamp":1790095140379,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"crossref","award":["JP256f0137008"],"award-info":[{"award-number":["JP256f0137008"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Promotion of Science (JSPS) KAKENHI","award":["21K09365"],"award-info":[{"award-number":["21K09365"]}]},{"name":"the Center for Cyber Medicine Research"},{"DOI":"10.13039\/501100020953","name":"COI-NEXT","doi-asserted-by":"crossref","award":["JPMJPF2017"],"award-info":[{"award-number":["JPMJPF2017"]}],"id":[{"id":"10.13039\/501100020953","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pretreatment immune profiles associated with immune-related adverse events (irAEs) may inform individualized management strategies, including enhanced monitoring and early toxicity intervention, in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab. In this cohort (n\u2009=\u200951), we analyzed pretreatment peripheral blood parameters and whole-blood transcriptomic profiles. Higher lymphocyte and monocyte counts (odds ratios [ORs] 14.36 and 9.90, respectively) were significantly associated with an increased risk of irAEs, whereas higher neutrophil counts and C-reactive protein levels (ORs 0.08 and 0.27, respectively) were associated with a decreased risk. To characterize immune pathways associated with irAE development, we performed whole-blood transcriptomic analyses. Gene set enrichment analysis revealed upregulation of lymphocyte- and humoral immunity-related pathways and downregulation of neutrophil- and inflammatory-related pathways in patients who developed irAEs. CIBERSORTx demonstrated reduced neutrophil fractions and increased proportions of CD8\u207a T cells and activated memory CD4\u207a T cells, indicating an adaptive immune-dominant profile. Exploratory analysis identified five candidate genes (ANAPC1, CDK4, MCM6, GRAP2, and BST2) that may contribute to the immune features associated with irAE development. Collectively, these findings suggest that irAE development is associated with a distinct systemic immune profile characterized by enhanced lymphocyte-related and reduced neutrophil-related immune activity.<\/jats:p>","DOI":"10.1038\/s41598-026-46960-6","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T06:26:05Z","timestamp":1776925565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Blood parameters and whole-blood transcriptomics associated with immune-related adverse events in metastatic renal cell carcinoma during nivolumab plus ipilimumab"],"prefix":"10.1038","volume":"16","author":[{"given":"Satoka","family":"Kinase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Nagumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bunpei","family":"Isoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akane","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Yanagihashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozaburo","family":"Tanuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Kojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kawahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Hoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuya","family":"Kandori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan J.","family":"Mathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"46960_CR1","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","volume":"35","author":"NM Tannir","year":"2024","unstructured":"Tannir, N. M. et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann. Oncol. 35, 1026\u20131038 (2024).","journal-title":"Ann. Oncol."},{"key":"46960_CR2","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277\u20131290 (2018).","journal-title":"N. Engl. J. Med."},{"key":"46960_CR3","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.5306\/wjco.v15.i8.1002","volume":"15","author":"AJ Guo","year":"2024","unstructured":"Guo, A. J., Deng, Q. Y., Dong, P., Zhou, L. & Shi, L. Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors. World J. Clin. Oncol. 15, 1002\u20131020 (2024).","journal-title":"World J. Clin. Oncol."},{"key":"46960_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158017","author":"R Reschke","year":"2021","unstructured":"Reschke, R. et al. Distinct immune signatures indicative of treatment response and immune-related adverse events in melanoma patients under immune checkpoint inhibitor therapy. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22158017 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"46960_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.779691","volume":"13","author":"A Chennamadhavuni","year":"2022","unstructured":"Chennamadhavuni, A., Abushahin, L., Jin, N., Presley, C. J. & Manne, A. Risk factors and biomarkers for immune-related adverse events: A practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front. Immunol. 13, 779691 (2022).","journal-title":"Front. Immunol."},{"key":"46960_CR6","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/s41598-022-05400-x","volume":"12","author":"S Takayasu","year":"2022","unstructured":"Takayasu, S. et al. Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: A retrospective cohort study. Sci. Rep. 12, 1294 (2022).","journal-title":"Sci. Rep."},{"key":"46960_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0408-9","volume":"6","author":"P Friedlander","year":"2018","unstructured":"Friedlander, P. et al. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor Tremelimumab. J. Immunother. Cancer 6, 90 (2018).","journal-title":"J. Immunother. Cancer"},{"key":"46960_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-025-04155-4","volume":"74","author":"S Hone Lopez","year":"2025","unstructured":"Hone Lopez, S. et al. Upfront whole blood transcriptional patterns in patients receiving immune checkpoint inhibitors associate with clinical outcome. Cancer Immunol. Immunother. 74, 301 (2025).","journal-title":"Cancer Immunol. Immunother."},{"key":"46960_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7007-8-84","volume":"8","author":"D Chaussabel","year":"2010","unstructured":"Chaussabel, D., Pascual, V. & Banchereau, J. Assessing the human immune system through blood transcriptomics. BMC Biol. 8, 84 (2010).","journal-title":"BMC Biol."},{"key":"46960_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1093","volume":"8","author":"WA Figgett","year":"2019","unstructured":"Figgett, W. A. et al. Machine learning applied to whole-blood RNA-sequencing data uncovers distinct subsets of patients with systemic lupus erythematosus. Clin. Transl. Immunology. 8, e01093 (2019).","journal-title":"Clin. Transl. Immunology."},{"key":"46960_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02160-2","volume":"23","author":"S Chen","year":"2024","unstructured":"Chen, S. et al. A prospective multi-cohort study identifies and validates a 5-gene peripheral blood signature predictive of immunotherapy response in non-small cell lung cancer. Mol. Cancer 23, 247 (2024).","journal-title":"Mol. Cancer"},{"key":"46960_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/cc11477","volume":"16","author":"GP Parnell","year":"2012","unstructured":"Parnell, G. P. et al. A distinct influenza infection signature in the blood transcriptome of patients with severe community-acquired pneumonia. Crit. Care 16, R157 (2012).","journal-title":"Crit. Care"},{"key":"46960_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246207","author":"Y Nagumo","year":"2022","unstructured":"Nagumo, Y. et al. Whole-blood gene expression profiles correlate with response to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma. Cancers https:\/\/doi.org\/10.3390\/cancers14246207 (2022).","journal-title":"Cancers"},{"key":"46960_CR14","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3390\/jpm12060888","volume":"12","author":"K Nishimura","year":"2022","unstructured":"Nishimura, K. et al. CD21(lo) B cells could be a potential predictor of immune-related adverse events in renal cell carcinoma. J. Pers. Med. 12, 888 (2022).","journal-title":"J. Pers. Med."},{"key":"46960_CR15","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/iju.15220","volume":"30","author":"Y Tasaki","year":"2023","unstructured":"Tasaki, Y. et al. Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma. Int. J. Urol. 30, 866\u2013874 (2023).","journal-title":"Int. J. Urol."},{"key":"46960_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006437","volume":"11","author":"J Ostmeyer","year":"2023","unstructured":"Ostmeyer, J. et al. T-cell tolerant fraction as a predictor of immune-related adverse events. J. Immunother. Cancer 11, e006437 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"46960_CR17","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.3390\/nu14112242","volume":"14","author":"S Choi","year":"2022","unstructured":"Choi, S. et al. Gene set enrichment analysis reveals that fucoidan induces type I IFN pathways in BMDC. Nutrients 14, 2242 (2022).","journal-title":"Nutrients"},{"key":"46960_CR18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"46960_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"2018","unstructured":"Tibshirani, R. Regression shrinkage and selection via the lasso. J. Roy. Stat. Soc. Ser. B Methodol. 58, 267\u2013288 (2018).","journal-title":"J. Roy. Stat. Soc. Ser. B Methodol."},{"key":"46960_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2016.00344","volume":"10","author":"SV Abram","year":"2016","unstructured":"Abram, S. V. et al. Bootstrap enhanced penalized regression for variable selection with neuroimaging data. Front. Neurosci. 10, 344 (2016).","journal-title":"Front. Neurosci."},{"issue":"Suppl 2","key":"46960_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1753-6561-6-S2-S10","volume":"6","author":"JO Ogutu","year":"2012","unstructured":"Ogutu, J. O., Schulz-Streeck, T. & Piepho, H. P. Genomic selection using regularized linear regression models: ridge regression, lasso, elastic net and their extensions. BMC Proc. 6(Suppl 2), S10 (2012).","journal-title":"BMC Proc."},{"key":"46960_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1\u201322 (2010).","journal-title":"J. Stat. Softw."},{"key":"46960_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-7-91","volume":"7","author":"S Varma","year":"2006","unstructured":"Varma, S. & Simon, R. Bias in error estimation when using cross-validation for model selection. BMC Bioinform. 7, 91 (2006).","journal-title":"BMC Bioinform."},{"key":"46960_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/stats4040051","author":"Y Chen","year":"2021","unstructured":"Chen, Y. & Yang, Y. The One Standard Error Rule for Model Selection: Does It Work?. Stats https:\/\/doi.org\/10.3390\/stats4040051 (2021).","journal-title":"Stats"},{"key":"46960_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin, X. et al. pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform. 12, 77 (2011).","journal-title":"BMC Bioinform."},{"key":"46960_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman, A. M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453\u2013457 (2015).","journal-title":"Nat. Methods"},{"key":"46960_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061308","author":"PY Lee","year":"2021","unstructured":"Lee, P. Y. et al. Neutrophil-to-lymphocyte ratio predicts development of immune-related adverse events and outcomes from immune checkpoint blockade: A case-control study. Cancers https:\/\/doi.org\/10.3390\/cancers13061308 (2021).","journal-title":"Cancers"},{"key":"46960_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-88307-3","volume":"11","author":"D Michailidou","year":"2021","unstructured":"Michailidou, D. et al. Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors. Sci. Rep. 11, 9029 (2021).","journal-title":"Sci. Rep."},{"key":"46960_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00119","volume":"6","author":"Y Nakamura","year":"2019","unstructured":"Nakamura, Y. Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events. Front. Med. 6, 119 (2019).","journal-title":"Front. Med."},{"key":"46960_CR30","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11523-020-00707-z","volume":"15","author":"IY Sheng","year":"2020","unstructured":"Sheng, I. Y. et al. Blood myeloid-derived suppressor cells correlate with neutrophil-to-lymphocyte ratio and overall survival in metastatic urothelial carcinoma. Target. Oncol. 15, 211\u2013220 (2020).","journal-title":"Target. Oncol."},{"key":"46960_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01657-y","volume":"21","author":"Y Wu","year":"2022","unstructured":"Wu, Y., Yi, M., Niu, M., Mei, Q. & Wu, K. Myeloid-derived suppressor cells: An emerging target for anticancer immunotherapy. Mol. Cancer 21, 184 (2022).","journal-title":"Mol. Cancer"},{"key":"46960_CR32","doi-asserted-by":"publisher","first-page":"S1488","DOI":"10.1016\/j.annonc.2022.10.177","volume":"33","author":"R Kizawa","year":"2022","unstructured":"Kizawa, R. et al. 142P The predictive biomarker for immune-related adverse events (irAEs) in patients with metastatic renal cell carcinoma treated with the combination therapy of nivolumab plus ipilimumab: Musashino study-irAE. Ann. Oncol. 33, S1488 (2022).","journal-title":"Ann. Oncol."},{"key":"46960_CR33","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.4049\/jimmunol.180.5.3492","volume":"180","author":"T Nishikawa","year":"2008","unstructured":"Nishikawa, T. et al. Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 alpha is essential for cytokine-driven C-reactive protein gene expression. J. Immunol. 180, 3492\u20133501 (2008).","journal-title":"J. Immunol."},{"key":"46960_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0161-5890(01)00042-6","volume":"38","author":"JE Volanakis","year":"2001","unstructured":"Volanakis, J. E. Human C-reactive protein: Expression, structure, and function. Mol. Immunol. 38, 189\u2013197 (2001).","journal-title":"Mol. Immunol."},{"key":"46960_CR35","doi-asserted-by":"publisher","first-page":"9503","DOI":"10.1074\/jbc.271.16.9503","volume":"271","author":"D Zhang","year":"1996","unstructured":"Zhang, D., Sun, M., Samols, D. & Kushner, I. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J. Biol. Chem. 271, 9503\u20139509 (1996).","journal-title":"J. Biol. Chem."},{"key":"46960_CR36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.724","volume":"41","author":"L Carril-Ajuria","year":"2023","unstructured":"Carril-Ajuria, L. Baseline circulating soluble factors as predictors of immune-related adverse events (irAEs) in patients with metastatic clear cell renal carcinoma (mRCC) treated with nivolumab: A translational NIVOREN GETUG-AFU 26 study. J. Clin. Oncol. 41, 724 (2023).","journal-title":"J. Clin. Oncol."},{"key":"46960_CR37","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41573-021-00259-5","volume":"21","author":"RJ Sullivan","year":"2022","unstructured":"Sullivan, R. J. & Weber, J. S. Immune-related toxicities of checkpoint inhibitors: Mechanisms and mitigation strategies. Nat. Rev. Drug Discov. 21, 495\u2013508 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"46960_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16091759","author":"L Alserawan","year":"2024","unstructured":"Alserawan, L. et al. Kinetics of IFN\u03b3-induced cytokines and development of immune-related adverse events in patients receiving PD-(L)1 inhibitors. Cancers https:\/\/doi.org\/10.3390\/cancers16091759 (2024).","journal-title":"Cancers"},{"key":"46960_CR39","unstructured":"He, L. et al. CDK4\/6 inhibition induces CD8(+) T cell antitumor immunity via MIF-induced functional orchestration of tumor-associated macrophages. Adv. Sci. e11330 (2025)."},{"key":"46960_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/10732748251330059","volume":"32","author":"Y Chen","year":"2025","unstructured":"Chen, Y. et al. The potential biological roles and clinical significance of anaphase-promoting complex subunit 1 in colorectal cancer. Cancer Control 32, 10732748251330059 (2025).","journal-title":"Cancer Control"},{"key":"46960_CR41","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cca.2021.02.005","volume":"517","author":"T Zeng","year":"2021","unstructured":"Zeng, T. et al. The DNA replication regulator MCM6: An emerging cancer biomarker and target. Clin. Chim. Acta 517, 92\u201398 (2021).","journal-title":"Clin. Chim. Acta"},{"key":"46960_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-75","volume":"11","author":"V Shahabi","year":"2013","unstructured":"Shahabi, V. et al. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. J. Transl. Med. 11, 75 (2013).","journal-title":"J. Transl. Med."},{"key":"46960_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.01152","volume":"10","author":"G Marco-Puche","year":"2019","unstructured":"Marco-Puche, G., Lois, S., Ben\u00edtez, J. & Trivino, J. C. RNA-Seq perspectives to improve clinical diagnosis. Front. Genet. 10, 1152 (2019).","journal-title":"Front. Genet."},{"key":"46960_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00447","volume":"10","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Changing technologies of RNA sequencing and their applications in clinical oncology. Front. Oncol. 10, 447 (2020).","journal-title":"Front. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46960-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46960-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46960-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T12:04:35Z","timestamp":1781697875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46960-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["46960"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-46960-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Aspects of the present study involving human participants were reviewed and approved by the University of Tsukuba Hospital Institutional Review Board (#H28-104). All procedures were performed in accordance with relevant guidelines and regulations and with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written, informed consent to participate in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"18800"}}